RT Journal Article
SR Electronic
T1 Association of circulating miR-223 and miR-16 with disease activity in patients with early rheumatoid arthritis
JF Annals of the Rheumatic Diseases
JO Ann Rheum Dis
FD BMJ Publishing Group Ltd and European League Against Rheumatism
SP 1898
OP 1904
DO 10.1136/annrheumdis-2012-202815
VO 73
IS 10
A1 Mária Filková
A1 Borbala Aradi
A1 Ladislav Šenolt
A1 Caroline Ospelt
A1 Serena Vettori
A1 Heřman Mann
A1 Andrew Filer
A1 Karim Raza
A1 Christopher D Buckley
A1 Martyn Snow
A1 Jiří Vencovský
A1 Karel Pavelka
A1 Beat A Michel
A1 Renate E Gay
A1 Steffen Gay
A1 Astrid Jüngel
YR 2014
UL http://ard.bmj.com/content/73/10/1898.abstract
AB Background Identification of parameters for early diagnosis and treatment response would be beneficial for patients with early rheumatoid arthritis (ERA) to prevent ongoing joint damage. miRNAs have features of potential biomarkers, and an altered expression of miRNAs was shown in established rheumatoid arthritis (RA). Objective To analyse RA associated miRNAs in the sera of patients with ERA to find markers of early disease, clinical activity or predictors of disease outcome. Methods Total RNA was isolated from whole sera in ERA patients (prior to and after 3 and 12 months of therapy with disease modifying antirheumatic drugs), in patients with established RA and in healthy controls (HC) using phenol–chloroform extraction. Expression of miR-146a, miR-155, miR-223, miR-16, miR-203, miR-132 and miR-124a was analysed by TaqMan Real Time PCR. Results From all analysed miRNAs, levels of miR-146a, miR-155 and miR-16 were decreased in the sera of ERA patients in comparison with established RA. A change in circulating miR-16 in the first 3 months of therapy was associated with a decrease in DAS28 in long term follow-up in ERA (p=0.002). Levels of circulating miR-223 in treatment naïve ERA correlated with C reactive protein (p=0.008), DAS28 (p=0.031) and change in DAS28 after 3 months (p=0.003) and 12 months (p=0.011) of follow-up. However, neither miR-16 nor miR-223 could distinguish ERA from HC. Conclusions Differential expression of circulating miR-146a, miR-155 and miR-16 in the sera of ERA patients may characterise an early stage of the disease. We suggest miR-223 as a marker of disease activity and miR-16 and miR-223 as possible predictors for disease outcome in ERA.